Background: The quality of life of Gastro Esophageal Reflux Disease (GERD) patients will consistently decline both physically and psychologically compared to the general population. WHOQOL-BREF is a questionnaire to evaluate the quality of life with high validity and reliability. One of GERD therapy is a proton pump inhibitor (PPI). There are studies on PPI administration in GERD patients worldwide, however in Indonesia there is limited research evaluating how PPI especially Omeprazole influences the quality of life in GERD. We determined the effect of omeprazole to the quality of life of patients with GERD. Methods: GERD questionnaires (GERDQ) was used to determine life quality of GERD patients and interpretation was performed based on score obtained. The comparison between the perception of the quality of life and perception of health satisfaction in GERD patients before and after Omeprazole administration was analyzed using Wilcoxon signed rank test. While, the comparison of the quality of life based on WHOQOL-BREF before and after administration of omeprazole was analyzed using Wilcoxon signed rank test and t-test. Results: We included 43 GERD patients with the mean age of 39.50±5.71 years. The most complaints were nausea, pain in the upper middle part of the stomach and heartburn (88.4%; 81.4% and 79.1%, respectively). There was a significant difference in the perception of quality of life (p=0.000) and the perception of health satisfaction (p=0.001) but, there was no significant difference in WHOQOL-BREF scores before and after Omeprazole administration (each domains of physical, social, psychological, environmental was p=0.275; p=0.380; p=0.199; p=0.810 respectively). Conclusion: Omeprazole did not improve the quality of life of GERD patients.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalNew Armenian Medical Journal
Issue number1
Publication statusPublished - 2019


  • Gastroesophageal-reflux disease
  • Quality of life


Dive into the research topics of 'The effect of omeprazole administration to the quality of life of gastro esophageal reflux disease patients'. Together they form a unique fingerprint.

Cite this